Equity Overview
Price & Market Data
Price: $2.13
Daily Change: +$0.02 / 0.94%
Daily Range: $2.10 - $2.18
Market Cap: $8,097,419
Daily Volume: 17,399
Performance Metrics
1 Week: -1.84%
1 Month: -4.05%
3 Months: -14.80%
6 Months: -28.28%
1 Year: -80.11%
YTD: -79.60%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.